1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Enzon Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Enzon Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 49 pages

Enzon Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Enzon Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Enzon Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Enzon Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Enzon Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Enzon Pharmaceuticals, Inc. - Brief Enzon Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Enzon Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Enzon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Enzon Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Enzon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Enzon Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Enzon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Enzon Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Enzon Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Enzon Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Enzon Pharmaceuticals, Inc. Snapshot 5
Enzon Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Enzon Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Enzon Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Enzon Pharmaceuticals, Inc. - Pipeline Products Glance 10
Enzon Pharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Enzon Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Enzon Pharmaceuticals, Inc. - Drug Profiles 14
Anti-Cancer Program 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
EZN-2968 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
EZN-3920 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
EZN-4176 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
firtecan pegol 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
pegylated interferon beta-1b 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Enzon Pharmaceuticals, Inc. - Pipeline Analysis 23
Enzon Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 23
Enzon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24
Enzon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 25
Enzon Pharmaceuticals, Inc. - Recent Pipeline Updates 26
Enzon Pharmaceuticals, Inc. - Dormant Projects 29
Enzon Pharmaceuticals, Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
EZN-2232 30
ENZ-3042 30
firtecan pegol 30
pegamotecan 31
Enzon Pharmaceuticals, Inc. - Company Statement 32
Enzon Pharmaceuticals, Inc. - Locations And Subsidiaries 33
Head Office 33
Other Locations and Subsidiaries 33
Enzon Pharmaceuticals, Inc., Recent Developments 34
Enzon Pharmaceuticals, Inc.- Press Release 34
Dec 15, 2010: Enzon Starts Phase I Study of EZN-2208 In Collaboration With National Cancer Institute 34
Oct 05, 2010: Enzon Announces Preclinical Study Data Of PEG-SN38 In Pediatric Neuroblastoma 35
Feb 24, 2010: Enzon Opens Pediatric Study Of PEG-SN38 36
Feb 10, 2010: Enzon Discontinues Further Development of rhMBL 36
Jan 06, 2010: Enzon Initiates Phase II Study Of PEG-SN38 For The Treatment Of Metastatic Breast Cancer 36
Financial Deals Landscape 37
Enzon Pharmaceuticals, Inc., Deals Summary 37
Enzon Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 38
Partnerships 38
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 38
Licensing Agreements 40
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 40
Enzon Pharma Enters Into Licensing Agreement With NOF 42
Asset Transactions 43
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 43
Drug Royalty Corporation Acquires 25% Stake In Enzon's PEG-INTRON 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49



List of Tables

Enzon Pharmaceuticals, Inc., Key Information 5
Enzon Pharmaceuticals, Inc., Key Facts 5
Enzon Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Enzon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Enzon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Enzon Pharmaceuticals, Inc. - Phase II, 2013 10
Enzon Pharmaceuticals, Inc. - Phase I, 2013 11
Enzon Pharmaceuticals, Inc. - Pre-Clinical, 2013 12
Enzon Pharmaceuticals, Inc. - Discovery, 2013 13
Enzon Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 23
Enzon Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 24
Enzon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 25
Enzon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 26
Enzon Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 29
Enzon Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 30
Enzon Pharmaceuticals, Inc., Other Locations 33
Enzon Pharmaceuticals, Inc., Subsidiaries 33
Enzon Pharmaceuticals, Inc., Deals Summary 37
Enzon Pharma Enters Into Co-Development Agreement With Zhejiang Hisun Pharma 38
Enzon Pharma Enters Into Licensing Agreement With Zhejiang Hisun Pharma For PEG-SN38 40
Enzon Pharma Enters Into Licensing Agreement With NOF 42
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 43
Drug Royalty Corporation Acquires 25% Stake In Enzon's PEG-INTRON 46



List of Figures

Enzon Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Enzon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Enzon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Enzon Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 24
Enzon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.